5th July 2023 6:00PM BST - Virtual
Real world experience treating WM and what’s next for CLL
This promotional meeting, sponsored by BeiGene, brought together a group of clinical experts to discuss their experience of treating patients with Waldenstrom’s Macroglobulinaemia using BRUKINSA®▼ (zanubrutinib), a next generation BTK inhibitor. This meeting involved sharing case studies and discussing the role of BRUKINSA in treatment pathways and hospital protocols. The second part of the meeting focused on the role of BRUKINSA (zanubrutinib) in treating Chronic Lymphocytic Leukaemia (CLL).
Agenda
Recordings
Welcome to “Real world experience treating WM and what’s next for CLL” – Dr Robert Mulrooney
Waldenström’s macroglobulinaemia/ lymphoplasmacytic lymphoma: An introduction – Prof George Follows
Case-based panel discussion – Dr Pam McKay
Case-based panel discussion – Dr Sarah Lawless
Case-based panel discussion – Dr Vishal Jayakar
BTK inhibitor choices in CLL: What’s next for zanubrutinib in CLL? – Dr Toby Eyre
Closing
Date of preparation: July 2023. 0723-BRU-PRC-082
Speakers
Prof George Follows
Addenbrooks Hospital
He is a former chair of the UK CLL Forum and CLL Guidelines Panel and Research Lead for haematology clinical trials at the Cambridge Cancer Trials Centre. He currently chairs the UK Hodgkin Lymphoma Guidelines Panel and is an Associate Professor affiliated to the University of Cambridge Department of Haematology.
Dr Pam McKay
Beatson West of Scotland Cancer Centre
Dr McKay is a Consultant Haematologist at the Beatson, West of Scotland Cancer Centre and an Honorary Clinical Associate Professor at the University of Glasgow School of Medicine. She has a specialist interest in lymphoma and is actively involved in lymphoma at a regional and national level. She is currently a member of the NCRI Lymphoma Clinical Studies Group and the high-grade lymphoma and Hodgkin’s lymphoma Clinical Studies Subgroups.
Dr Toby Eyre
Oxford University Hospitals NHS Foundation Trust
Dr Toby Eyre is a consultant haematologist at Oxford University Hospitals NHS Foundation Trust specialising in the management of lymphoid malignancies. He is an expert in the management of patients with lymphoma and patients with chronic lymphocytic leukaemia. He is the current BSH-NIHR Researcher of the year in 2021 and an Associate Editor at the British Journal of Haematology.
Dr Sarah Lawless
Belfast City Hospital
Dr Lawless specialises in lymphoma, myeloma and haematopoietic stem cell transplantation. Dr Lawless began her career in haematology at BCH in 2008 and she currently holds the position of speciality improvement and SACT lead at Belfast City Hospital. She is actively involved in clinical trials and is a member of UK NCRI group and is the invited regional N. Ireland representative on the UK Myeloma Society executive committee.
Dr Vishal Jayakar
Kingston Hospital NHS Foundation Trust
After completing his medical education and postgraduate training in internal medicine from King Edward Memorial Hospital in Mumbai, India with 7 distinctions, Dr Jayakar did haematology SHO jobs at UCL and Royal Marsden, London whilst acquiring his MRCP qualification. He has been a Consultant Haematologist at Kingston Hospital, London since 2011. He also co-organises the venerable Imperial Morphology Courses with Prof Barbara Bain and has a honorary lecturer contract at Imperial College, London.